Alliance Pharma Regulatory News (APH)

RNS Number : 8545O

Alliance Pharma PLC

06 July 2010

 

For immediate release

6 July 2010

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Pre-Close Trading Update

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces a pre-close trading update ahead of its interim results for the six months ended 30 June 2010.

 

Trading continues to be strong with sales for the six months ended 30 June 2010 of approximately £23.4m, an increase of £10.2m on the first half of 2009. Excluding revenue from products acquired over the past year, sales increased over the first half of last year by approximately 40%.

 

Deltacortril / enteric coated prednisolone sales have continued to be strong. Total sales by Alliance of the products acquired from Cambridge Laboratories in February 2010 have been in line with our expectations in the period ended 30 June 2010.

 

The Company's interim results for the six months ended 30 June 2010 are scheduled to be released on 8 September 2010.

 

 

 

 

For further information:

 

Alliance Pharma plc	+ 44 (0) 1249 466 966
John Dawson, Chief Executive Officer
Richard Wright, Finance Director
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney

 

Notes to editors:

 

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

 

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed both to hospitals directly and to pharmaceutical wholesalers, which in turn service both hospital and retail pharmacies with their prescription requirements.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange